CRM vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-20.
Salesforce, Inc. · Technology
$182.14
+45.0% upside to fair value
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+45.0%).
CRM trades at a lower forward P/E
(22.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
JNJ |
| Current Price |
$182.14 |
$230.69 |
| Fair Value Estimate |
$264.10 |
$255.61 |
| Upside to Fair Value |
+45.0%
|
+10.8%
|
| Market Cap |
$173.0B |
$555.9B |
| Forward P/E |
22.8x
|
26.8x
|
| EV / EBITDA |
14.4x
|
18.5x
|
| Price / Sales |
4.2x
|
5.8x
|
| Price / FCF |
12.0x
|
28.2x
|
| Revenue Growth YoY |
+12.1%
|
+9.9%
|
| Gross Margin |
77.7%
|
69.1%
|
| Operating Margin |
21.5%
|
26.9%
|
| Return on Equity |
12.4%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
8.33%
|
3.54%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Salesforce, Inc. is a leading enterprise software company specializing in cloud-based customer relationship management and enterprise applications. The company benefits from a durable competitive moat anchored by pioneering SaaS delivery, a large and growing customer base, and a diversified revenue mix with Service Cloud as the largest segment generating $9.05 billion in FY2025. Salesforce exhibi…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
CRM |
JNJ |
| Zone Low |
$198.08 |
$191.71 |
| Zone High |
$224.49 |
$217.27 |
| In Buy Zone? |
Yes
|
No
|